Subclinical Cardiac Dysfunction in Sarcoidosis (7)

Subclinical Cardiac Dysfunction in Sarcoidosis (7)Seventy-seven percent of the patients with sarcoidosis were symptomatic by questionnaire at the time of the study (Table 1). Symptoms included exertional dyspnea in 23, easy fatigability in eight, and palpitations in two. Thirteen patients had stage 1 chest roentgenograms, 14 had stage 2 chest roentgenograms, and eight had stage 3 chest roentgenograms. Nineteen had never received corticosteroid therapy, while 12 were receiving corticosteroid therapy at the time of the study, and four had received corticosteroids prior to the study.

PFTs
Results of pulmonary {unction studies in the group with sarcoidosis and normal controls are shown in Table 2. Although forced vital capacity and FEVj were significantly lower in the patients with sarcoidosis than controls, the patients’ results were within the normal range. Group mean single breath diffusing capacity (Deo) and total lung capacity (TLC) were normal in the patients with sarcoidosis. Fifteen patients had abnormal pulmonary function tests, including ten with reduced FVC, eight with reduced Deo, and four with reduced TLC. Buy Advair Diskus Online
Resting ECGs and 24-Hour ECG Recordings
Results of ECGs recorded at rest in the control subjects and in the patients with sarcoidosis are presented in Table 2. Twenty-eight patients had normal resting ECGs. Sinus tachycardia, ie, resting HR greater than 100 beats per minute, was present on the ECG of three patients. Right bundle branch block was found in three other patients. Sinus bradycardia (ie, resting HR <60 beats per minute) was noted in only one patient.

Table 2—Symptoms, ECG, Pulmonary Function Test Data, Exercise Data, Continuous Ambulatory ECG Data, and RNA Data Grouped by Roentgenographic Stage

HR
PatientNo. X-RayStage SXS ECG FEV„%pred FVC,%pned Deo,%pred TLC,%pred SHR,%pred Rest HR, bpm MAX HR, %pred Vo*ml/min/K Vo„%pred AT, %pred Vo 1* SVE MAXVE,%MW (18-23h) (0-5h) (6-1 lh) LVEF,%
1 1 0 NSR 97 81 99 104 87.8 96 91 20.0 80 47.3 31.2 73 44
2 1 DOE,FTG NSR 70 74 89 104 97.7 83 65 11.9 42 33.6 27.1 35 99.2 76.4 97.0 47
3 1 FTG, DOE NSR 93 91 81 97 105.5 90 88 47.2 76 41.0 24.2 74
4 1 0 NSR 106 105 109 137 111.6 73 96 19.2 65 36.2 26.8 47 62
5 1 FTG NSR 120 96 113 125 169.6 85 95 24.5 66 36.7 24.5 56 39
6 1 DOE NSR 108 101 105 116 100.2 76 91 22.5 64 40.5 31.1 58 84.8 70.1 95.6 52
7 1 0 NSR 97 90 110 91 58.6 70 79 35.3 78 39.6 24.5 54 73
8 1 0 NSR 127 121 100 108 64.0 86 104 47.9 106 86.8 31.4 76 82.7 66.5 85.2 37
9 1 0 NSR 122 114 133 116 52.0 77 90 40.0 107 66.1 28.4 85 65
10 1 DOE NSR 101 101 108 98 112.3 90 99 48.3 115 85.9 31.0 80
11 1 PALP,FTG ST 95 90 116 106 131.8 127 91 27.1 52 29.1 27.0 28 101.4 85.8 72.3 61
12 1 DOE NSR 120 116 92 118 121.2 79 84 34.4 82 40.8 21.9 69 76.9 70.1 61.1 49
13 1 DOE NSR 86 73 95 90 112.9 77 71 18.8 50 33.5 26.0 38 86.9 69.9 88.0 57
Mean 103.2 96.4 103.8 108.5 101.9 85.3 88.0 30.5 75.6 47.5 27.3 59.5 88.6 73.1 83.2 53.5
SD 16.2 15.3 13.4 14.2 31.9 14.6 10.9 12.4 22.7 19.5 3.1 18.4 9.7 7.0 14.0 11.4
14 2 DOE SB 83 83 66 103 66.2 64 74 17.0 66 48.0 60
15 2 DOE,CP NSR 63 78 80 107 82.7 72 73 15.3 56 37.7 39.6 50 71.9 65.0 79.2 55
16 2 DOE NSR 77 77 84 92 114.0 107 82 13.0 53 43.6 31.0 57 89.5 80.5 81.8 34
17 2 DOE,FTG NSR 67 60 87 72 187.1 88 93 19.6 53 23.9 30.1 53 97.0 70.7 89.5 32
18 2 DOE NSR 76 81 66 77 168.0 110 80 19.7 58 38.6 41.6 74 83.9 70.1 72.0 52
19 2 DOE NSR 103 97 82 105 151.2 77 91 17.7 49 35.3 24.5 38 53
20 2 0 NSR 83 81 74 86 118.2 75 92 40.3 76 49.3 29.5 93 99.7 72.3 72.9 52
21 2 DOE NSR 81 80 NA 80 131.2 79 92 31.9 67 29.6 24.2 45
22 2 0 NSR+RBBB 139 136 135 127 74.9 67 101 37.5 103 79.5 31.4 99 71.2 52.7 60.3 65
23 2 DOE NSR 109 100 111 88 67.5 83 94 20.5 79 32.1 37.1 92 99.6 76.0 79.3 61
24 2 DOE,FTG NSR 80 70 71 90 80.3 96 88 16.9 52 40.4 46.3 55
25 2 DOE NSR 85 89 66 96 135.9 91 79 20.0 45 26.1 29.9 50 70
26 2 0 NSR 92 83 95 88 77.3 76 80 17.7 67 38.3 28.8 57 54
27 2 DOE NSR 47 44 57 57 105.8 100 88 23.8 65 38.6 36.4 67 48
Mean 84.6 82.8 82.6 96.6 111.5 84.6 86.2 22.2 63.5 39.4 34.2 63.6 87.6 60.6 76.4 52.4
SD 22.0 20.8 21.3 17.7 39.1 14.5 8.3 8.3 15.1 13.9 7.5 19.0 12.3 8.9 9.2 11.5
28 3 FTG NSR+RBBB 100 91 140 108 129.1 71 65 10.0 33 22.4 25.6 37 72.7 62.6 68.3 31
29 3 FTG ST 83 82 68 92 168.9 123 91 21.3 51 27.3 30.0 41 74
30 3 DOE NSR+RBBB 115 104 76 120 80.4 80 69 16.3 49 43.3 30.2 51
31 3 DOE NSR 65 76 80 74 177.6 111 86 23.4 54 34.2 25.0 42 99.4 70.4 89.8 58
32 3 DOE NSR 102 96 70 93 105.1 74 83 28.2 63 37.2 31.5 66 68
33 3 DOE NSR 67 67 94 83 185.2 110 91 14.2 59 25.2 35.1 45 90.8 71.2 92.3 53
34 3 DOE NSR 82 71 96 88 217.2 85 104 18.3 45 38.8 44.5 74 91.7 81.5 84.2 42
35 3 DOE NSR 37 53 108 100 120.7 116 87 15.2 46 38.6 25.2 70
Mean 81.4 80.0 91.5 94.8 148.0 96.3 84.5 18.4 50.0 33.4 30.9 53.3 88.6 71.4 83.6 54.3
SD 24.9 16.7 24.0 15.5 46.3 20.8 12.5 5.8 9.2 7.5 6.5 14.6 11.3 7.8 10.7 16.0
Sarcoidosis
Mean 90.8t 87.2t 92.8 98.2 116.3 87.5f 86.5 24.4f 64.9t 41.lt 30.9t 59.7 88.2t 71.3t 80.5t 53.lt
SD 22.4 18.9 21.0 16.9 41.3 16.4 10.1 10.6 19.6 15.9 6.6 17.8 10.5 7.6 11.3 12.0
Normal controls
Mean 102.3 99.9 NA NA 110.4 76.2 89.1 33.5 81.2 53.8 26.1 60.2 77.1 62.6 66.7 63.7
SD 15.0 13.3 NA NA 22.5 12.4 7.4 5.9 12.3 11.8 3.5 17.9 4.5 7.7 6.2 10.4
anosiahuman.com